Fiztasovimab
Product Specifications
UNSPSC Description
Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV[1].
Target Antigen
CMV
Type
Inhibitory Antibodies
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/fiztasovimab.html
Purity
96.49
Solubility
10 mM in DMSO
Smiles
[Fiztasovimab]
References & Citations
[1]Furihata K, et al. Pharmacokinetics, Safety, and Tolerability of NPC-21, an Anti-Cytomegalovirus Monoclonal Antibody, in Healthy Japanese and White Adult Men: A Randomized, Placebo-Controlled, First-in-Human Phase 1 Study. Clin Pharmacol Drug Dev. 2022 Jun;11(6):707-716.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99621/Fiztasovimab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99621/Fiztasovimab-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
2467411-25-0
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
